Deutsche Bank Ag\ Humacyte, Inc. Transaction History

Deutsche Bank Ag\

$248 Billion
Q4 2024

A detailed history of Deutsche Bank Ag\ transactions in Humacyte, Inc. stock. As of the latest transaction made, Deutsche Bank Ag\ holds 78,474 shares of HUMA stock, worth $306,833. This represents 0.0% of its overall portfolio holdings.

Number of Shares

78,474

Previous 52,055 50.75%

Holding current value

$306,833

Previous $283,000 39.93%

% of portfolio

0.0%

Previous 0.0%

11 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2024 Feb 14, 2025	BUY	$3.46 - $5.81 $91,409 - $153,494	26,419 Added 50.75%	78,474 $396,000
Q3 2024 Nov 13, 2024	BUY	$5.11 - $9.46 $160,264 - $296,693	31,363 Added 151.57%	52,055 $283,000
Q2 2024 Aug 14, 2024	SELL	$2.87 - $9.1 $21,955 - $69,615	-7,650 Reduced 26.99%	20,692 $99,000
Q1 2024 May 15, 2024	SELL	$2.57 - $4.84 $2,898 - $5,459	-1,128 Reduced 3.83%	28,342 $88,000
Q4 2023 Feb 14, 2024	SELL	$1.99 - $3.12 $3,697 - $5,796	-1,858 Reduced 5.93%	29,470 $83,000
Q3 2023 Nov 09, 2023	SELL	$2.75 - $4.48 $800 - $1,303	-291 Reduced 0.92%	31,328 $91,000
Q2 2023 Aug 14, 2023	SELL	$2.86 - $4.97 $26,088 - $45,336	-9,122 Reduced 22.39%	31,619 $90,000
Q1 2023 May 15, 2023	BUY	$2.11 - $3.25 $32,506 - $50,069	15,406 Added 60.81%	40,741 $125,000
Q4 2022 Feb 13, 2023	BUY	$2.02 - $3.62 $36,707 - $65,782	18,172 Added 253.69%	25,335 $53,000
Q3 2022 Nov 14, 2022	SELL	$1.22 - $5.14 $1,439 - $6,065	-1,180 Reduced 14.14%	7,163 $23,000
Q2 2022 Aug 11, 2022	BUY	$3.21 - $7.86 $26,781 - $65,575	8,343 New	8,343 $27,000

Others Institutions Holding HUMA

# of Institutions

172

Shares Held

41.5M

Call Options Held

591K

Put Options Held

872K

View Full List

About Humacyte, Inc.

Ticker HUMA
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 103,007,000
Market Cap $403M
Description
Humacyte, Inc. engages in the development and manufacture of off-the-shelf, implantable, and bioengineered human tissues for the treatment of diseases and conditions across a range of anatomic locations in multiple therapeutic areas. The company using its proprietary and scientific technology platform to engineer and manufacture human acellular ...

More about HUMA

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Deutsche Bank Ag\, based on Form 13F filings with the SEC.

News

Stay updated on Deutsche Bank Ag\ with notifications on news.

Account